论文部分内容阅读
目的观察联合美罗华的改良CHOP方案治疗复发难治性非霍奇金淋巴瘤(NHL)的临床疗效和主要不良反应。方法 12例复发难治性NHL病人用改良方案治疗,21天为一周期,至少完成两周期治疗,评价治疗效果。结果全组12例患者均可评价疗效,6例CR,4例PR,2例PD,完全缓解率为50%,总有效率为83.3%。结论联合美罗华的改良CHOP方案可作为复发性难治性NHL的解救治疗方案。
Objective To observe the clinical efficacy and major adverse reactions of modified CHOP regimen combined with rituximab in the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). Methods Twelve patients with relapsed and refractory NHL were treated with a modified protocol. One cycle was 21 days, and at least two cycles of treatment were completed to evaluate the therapeutic effect. Results All 12 patients could evaluate the curative effect. The CR was 6 cases, the PR was 4 cases and the PD was 2 cases. The complete remission rate was 50% and the total effective rate was 83.3%. Conclusions The combined CHOP regimen of Rituximab can be used as a rescue treatment for recurrent refractory NHL.